The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

Yu Ri Kim; Soo Jeong Kim; June Won Cheong; Deok Hwan Yang; Hyewon Lee; Hyeon Seok Eom; Yong Oh Sung; Hyo Jung Kim; Hye Jin Kang; Won Sik Lee; Yong Park; Woo Ick Yang; Yoo Hong Min; Jin Seok Kim

doi:10.1007/s00277-016-2729-4

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

Yu Ri Kim, Soo Jeong Kim, June Won Cheong, Deok Hwan Yang, Hyewon Lee, Hyeon Seok Eom, Yong Oh Sung, Hyo Jung Kim, Hye Jin Kang, Won Sik Lee, Yong Park, Woo Ick Yang, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

Original language	English
Pages (from-to)	1491-1501
Number of pages	11
Journal	Annals of Hematology
Volume	95
Issue number	9
DOIs	https://doi.org/10.1007/s00277-016-2729-4
Publication status	Published - 2016 Sept 1

Bibliographical note

Funding Information:
This study was presented in the form of poster presentation at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 6–9, 2014. This work was supported by a faculty research grant from Yonsei University College of Medicine (6-2014-0096).

Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.

Keywords

Autologous hematopoietic stem cell transplantation
Diffuse large B cell lymphoma
Germinal center B cell
Non-germinal center B cell
Rituximab

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-016-2729-4

Fingerprint

Dive into the research topics of 'The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase'. Together they form a unique fingerprint.

Cite this

Kim, Y. R., Kim, S. J., Cheong, J. W., Yang, D. H., Lee, H., Eom, H. S., Sung, Y. O., Kim, H. J., Kang, H. J., Lee, W. S., Park, Y., Yang, W. I., Min, Y. H., & Kim, J. S. (2016). The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Annals of Hematology, 95(9), 1491-1501. https://doi.org/10.1007/s00277-016-2729-4

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. / Kim, Yu Ri; Kim, Soo Jeong; Cheong, June Won et al.
In: Annals of Hematology, Vol. 95, No. 9, 01.09.2016, p. 1491-1501.

Research output: Contribution to journal › Article › peer-review

Kim, YR, Kim, SJ, Cheong, JW, Yang, DH, Lee, H, Eom, HS, Sung, YO, Kim, HJ, Kang, HJ, Lee, WS, Park, Y, Yang, WI, Min, YH & Kim, JS 2016, 'The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase', Annals of Hematology, vol. 95, no. 9, pp. 1491-1501. https://doi.org/10.1007/s00277-016-2729-4

@article{32765687a0184a96804f906ccdc6b6b4,

title = "The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase",

abstract = "The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.",

keywords = "Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Germinal center B cell, Non-germinal center B cell, Rituximab",

author = "Kim, {Yu Ri} and Kim, {Soo Jeong} and Cheong, {June Won} and Yang, {Deok Hwan} and Hyewon Lee and Eom, {Hyeon Seok} and Sung, {Yong Oh} and Kim, {Hyo Jung} and Kang, {Hye Jin} and Lee, {Won Sik} and Yong Park and Yang, {Woo Ick} and Min, {Yoo Hong} and Kim, {Jin Seok}",

note = "Funding Information: This study was presented in the form of poster presentation at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 6–9, 2014. This work was supported by a faculty research grant from Yonsei University College of Medicine (6-2014-0096). Publisher Copyright: {\textcopyright} 2016, Springer-Verlag Berlin Heidelberg.",

year = "2016",

month = sep,

day = "1",

doi = "10.1007/s00277-016-2729-4",

language = "English",

volume = "95",

pages = "1491--1501",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

TY - JOUR

T1 - The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

AU - Kim, Yu Ri

AU - Kim, Soo Jeong

AU - Cheong, June Won

AU - Yang, Deok Hwan

AU - Lee, Hyewon

AU - Eom, Hyeon Seok

AU - Sung, Yong Oh

AU - Kim, Hyo Jung

AU - Kang, Hye Jin

AU - Lee, Won Sik

AU - Park, Yong

AU - Yang, Woo Ick

AU - Min, Yoo Hong

AU - Kim, Jin Seok

N1 - Funding Information: This study was presented in the form of poster presentation at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 6–9, 2014. This work was supported by a faculty research grant from Yonsei University College of Medicine (6-2014-0096). Publisher Copyright: © 2016, Springer-Verlag Berlin Heidelberg.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

AB - The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

KW - Autologous hematopoietic stem cell transplantation

KW - Diffuse large B cell lymphoma

KW - Germinal center B cell

KW - Non-germinal center B cell

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84975247303&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2729-4

DO - 10.1007/s00277-016-2729-4

M3 - Article

C2 - 27324387

AN - SCOPUS:84975247303

SN - 0939-5555

VL - 95

SP - 1491

EP - 1501

JO - Annals of Hematology

JF - Annals of Hematology

IS - 9

ER -

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this